Philippine trash trawlers earn little from virus-boosted surge in plastics

Many of the junkyards and businesses in Manila that buy recyclables have been closed since March. (File/AFP)
Updated 10 August 2020

Philippine trash trawlers earn little from virus-boosted surge in plastics

MANILA: Virgilio Estuesta has picked through trash in the Philippines’ biggest city for four decades, and is noticing an unusually large amount of plastics during his daily trawl of about 15 km (9.3 miles).
Tough curbs re-imposed to combat a surge in daily coronavirus infections are squeezing income for the 60-year-old, as many of the junkyards and businesses in Manila that buy his recyclables have been closed since March.
Plastic items, such as bottles and containers, dominate the contents of the rickety wooden cart Estuesta pushes through the deserted streets, far more than metals and cardboard, yet the money they bring in is not enough to get by.
“It’s been really hard for us, it’s been difficult looking for recyclables that sell high,” he said.
“Recently we’ve been seeing a lot more plastics, but the problem is they don’t really sell high.”
Environmentalists say the Philippines is battling one of the world’s biggest problems stemming from single-use plastics, and ranks among the biggest contributors to plastic pollution of the oceans. It has no reliable data for its plastics consumption.
Greenpeace campaigner Marian Ledesma said consumers and businesses are now using yet more single-use plastics, in a bid to ward off virus infections.
“The pandemic has really increased plastic pollution,” she added. “Just because there’s a lot more people using disposables now, due to misconceptions and fears around transmitting the virus.”
Since March 16, Manila has experienced lockdowns of varying levels of severity, in some of the world’s longest and tightest measures to curb the spread of the virus.
They are taking a toll on Estuesta, who hopes to start earning soon.
“When you go out, the police will reprimand you,” he said. “I was stuck at home and had to rely on government aid, which was not enough. I had to resort to borrowing money from people.”


Arthritis drug trialled as potential treatment for COVID-19

Updated 4 min 19 sec ago

Arthritis drug trialled as potential treatment for COVID-19

  • Dr. Andy Martin: We are conducting this study to see whether otilimab could potentially ease the effect of COVID- 19 on the lungs
  • Dr. Tim Felton: The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving

LONDON: The experimental arthritis drug, otilimab, is being trialled as a potential treatment for COVID-19.

The first patient, administered with the drug, is currently being cared for at Manchester Royal Infirmary (MRI), part of Manchester University NHS Foundation Trust (MFT).

The OSCAR study (Otilimab in Severe COVID-19 Related Disease) is sponsored and funded by the pharmaceutical company GlaxoSmithKline.

The study at the MRI is being led by Dr. Andy Martin, an Intensive Care and Anaesthesia Consultant.

Dr. Martin said: “The patients eligible to take part in this study are those experiencing very severe lung difficulties due to COVID-19 infection and are receiving oxygen or ventilator support.

“We are conducting this study to see whether otilimab — which is under investigation as a potential treatment for rheumatoid arthritis — could also potentially ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system.

Christopher Corsico, Senior Vice President Development, GSK said: “We are continuing to work hard to find solutions to address the pandemic, including exploring potential treatment options for COVID-19 patients.

“We know that some COVID-19 patients experience an overreaction of their immune system — sometimes referred to as cytokine storm — which can lead to hospitalization or death. We believe that otilimab might be able to help counter or calm this process.

Dr. Tim Felton, Honorary Consultant, Senior Lecturer at The University of Manchester and Clinical Lead for all MFT COVID-19-related research studies, leads OSCAR at Wythenshawe Hospital, which is also part of MFT.

Dr. Felton said: “The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving.

“I’d like to thank our first OSCAR participant — as well as the thousands of others who have taken part in coronavirus studies at MFT to date — as every participant who takes part in our research is contributing to the coordinated effort to enhance understanding of this global pandemic.”